Shocking Decision By EMA As It Rejects Alzheimer’s Drug from Eisai and Biogen
The European Medicines Agency has rejected the Alzheimer’s drug from Eisai and Biogen due to safety concerns. Learn more about the implications for Alzheimer’s treatment.
Leqembi rejection